This report provides a complete quantitative data and qualitative analysis on the global market for Human Microbiome Sequencing Technology. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Human Microbiome Sequencing Technology was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Human Microbiome Sequencing Technology is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Human Microbiome Sequencing Technology, including the following market information:
Global Human Microbiome Sequencing Technology Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Human Microbiome Sequencing Technology Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Human Microbiome Sequencing Technology Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Human Microbiome Sequencing Technology Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Baseclear B.V., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Charles River Laboratories International Inc., Clinical Microbiomics A/S, Eurofins Scientific SE, GENEWIZ, Inc., Illumina, Inc., Novogene Corporation, OraSure Technologies, Inc., Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., QIAGEN N.V., Second Genome, Inc., Thermo Fisher Scientific Inc., Viome, Inc., CosmosID, Leucine Rich Bio Pvt. Ltd., Microba, Microbiome Insights Inc., Molzym GmbH & Co. KG, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Traditional Sequencing Technologies
Next-Generation Sequencing
Third Generation Sequencing
Based on the Application:
Research and Academic Institutions
Pharmaceutical and Biotechnology Companies
Hospital and Clinic
Others
Prior to COVID-19, the global market for Human Microbiome Sequencing Technology was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Human Microbiome Sequencing Technology is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Human Microbiome Sequencing Technology, including the following market information:
Global Human Microbiome Sequencing Technology Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Human Microbiome Sequencing Technology Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Human Microbiome Sequencing Technology Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Human Microbiome Sequencing Technology Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Baseclear B.V., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Charles River Laboratories International Inc., Clinical Microbiomics A/S, Eurofins Scientific SE, GENEWIZ, Inc., Illumina, Inc., Novogene Corporation, OraSure Technologies, Inc., Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., QIAGEN N.V., Second Genome, Inc., Thermo Fisher Scientific Inc., Viome, Inc., CosmosID, Leucine Rich Bio Pvt. Ltd., Microba, Microbiome Insights Inc., Molzym GmbH & Co. KG, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Traditional Sequencing Technologies
Next-Generation Sequencing
Third Generation Sequencing
Based on the Application:
Research and Academic Institutions
Pharmaceutical and Biotechnology Companies
Hospital and Clinic
Others
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Human Microbiome Sequencing Technology Industry
1.7 COVID-19 Impact: Human Microbiome Sequencing Technology Market Trends
2 Global Human Microbiome Sequencing Technology Quarterly Market Size Analysis
2.1 Human Microbiome Sequencing Technology Business Impact Assessment - COVID-19
2.1.1 Global Human Microbiome Sequencing Technology Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Human Microbiome Sequencing Technology Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 By Players, Global Human Microbiome Sequencing Technology Quarterly Market Size, 2019 VS 2020
3.2 By Players, Human Microbiome Sequencing Technology Headquarters and Area Served
3.3 Date of Key Players Enter into Human Microbiome Sequencing Technology Market
3.4 Key Players Human Microbiome Sequencing Technology Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Human Microbiome Sequencing Technology Segments, By Type
4.1 Introduction
1.4.1 Traditional Sequencing Technologies
1.4.2 Next-Generation Sequencing
1.4.3 Third Generation Sequencing
4.2 By Type, Global Human Microbiome Sequencing Technology Market Size, 2019-2021
5 Impact of Covid-19 on Human Microbiome Sequencing Technology Segments, By Application
5.1 Overview
5.5.1 Research and Academic Institutions
5.5.2 Pharmaceutical and Biotechnology Companies
5.5.3 Hospital and Clinic
5.5.4 Others
5.2 By Application, Global Human Microbiome Sequencing Technology Market Size, 2019-2021
5.2.1 By Application, Global Human Microbiome Sequencing Technology Market Size by Application, 2019-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Baseclear B.V.
7.1.1 Baseclear B.V. Business Overview
7.1.2 Baseclear B.V. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.1.3 Baseclear B.V. Human Microbiome Sequencing Technology Product Introduction
7.1.4 Baseclear B.V. Response to COVID-19 and Related Developments
7.2 Beijing Genomics Institute (BGI) Genomics Co., Ltd
7.2.1 Beijing Genomics Institute (BGI) Genomics Co., Ltd Business Overview
7.2.2 Beijing Genomics Institute (BGI) Genomics Co., Ltd Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.2.3 Beijing Genomics Institute (BGI) Genomics Co., Ltd Human Microbiome Sequencing Technology Product Introduction
7.2.4 Beijing Genomics Institute (BGI) Genomics Co., Ltd Response to COVID-19 and Related Developments
7.3 Charles River Laboratories International Inc.
7.3.1 Charles River Laboratories International Inc. Business Overview
7.3.2 Charles River Laboratories International Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.3.3 Charles River Laboratories International Inc. Human Microbiome Sequencing Technology Product Introduction
7.3.4 Charles River Laboratories International Inc. Response to COVID-19 and Related Developments
7.4 Clinical Microbiomics A/S
7.4.1 Clinical Microbiomics A/S Business Overview
7.4.2 Clinical Microbiomics A/S Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.4.3 Clinical Microbiomics A/S Human Microbiome Sequencing Technology Product Introduction
7.4.4 Clinical Microbiomics A/S Response to COVID-19 and Related Developments
7.5 Eurofins Scientific SE
7.5.1 Eurofins Scientific SE Business Overview
7.5.2 Eurofins Scientific SE Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.5.3 Eurofins Scientific SE Human Microbiome Sequencing Technology Product Introduction
7.5.4 Eurofins Scientific SE Response to COVID-19 and Related Developments
7.6 GENEWIZ, Inc.
7.6.1 GENEWIZ, Inc. Business Overview
7.6.2 GENEWIZ, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.6.3 GENEWIZ, Inc. Human Microbiome Sequencing Technology Product Introduction
7.6.4 GENEWIZ, Inc. Response to COVID-19 and Related Developments
7.7 Illumina, Inc.
7.7.1 Illumina, Inc. Business Overview
7.7.2 Illumina, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.7.3 Illumina, Inc. Human Microbiome Sequencing Technology Product Introduction
7.7.4 Illumina, Inc. Response to COVID-19 and Related Developments
7.8 Novogene Corporation
7.8.1 Novogene Corporation Business Overview
7.8.2 Novogene Corporation Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.8.3 Novogene Corporation Human Microbiome Sequencing Technology Product Introduction
7.8.4 Novogene Corporation Response to COVID-19 and Related Developments
7.9 OraSure Technologies, Inc.
7.9.1 OraSure Technologies, Inc. Business Overview
7.9.2 OraSure Technologies, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.9.3 OraSure Technologies, Inc. Human Microbiome Sequencing Technology Product Introduction
7.9.4 OraSure Technologies, Inc. Response to COVID-19 and Related Developments
7.10 Oxford Nanopore Technologies, Inc.
7.10.1 Oxford Nanopore Technologies, Inc. Business Overview
7.10.2 Oxford Nanopore Technologies, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.10.3 Oxford Nanopore Technologies, Inc. Human Microbiome Sequencing Technology Product Introduction
7.10.4 Oxford Nanopore Technologies, Inc. Response to COVID-19 and Related Developments
7.11 Pacific Biosciences of California, Inc.
7.11.1 Pacific Biosciences of California, Inc. Business Overview
7.11.2 Pacific Biosciences of California, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.11.3 Pacific Biosciences of California, Inc. Human Microbiome Sequencing Technology Product Introduction
7.11.4 Pacific Biosciences of California, Inc. Response to COVID-19 and Related Developments
7.12 QIAGEN N.V.
7.12.1 QIAGEN N.V. Business Overview
7.12.2 QIAGEN N.V. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.12.3 QIAGEN N.V. Human Microbiome Sequencing Technology Product Introduction
7.12.4 QIAGEN N.V. Response to COVID-19 and Related Developments
7.13 Second Genome, Inc.
7.13.1 Second Genome, Inc. Business Overview
7.13.2 Second Genome, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.13.3 Second Genome, Inc. Human Microbiome Sequencing Technology Product Introduction
7.13.4 Second Genome, Inc. Response to COVID-19 and Related Developments
7.14 Thermo Fisher Scientific Inc.
7.14.1 Thermo Fisher Scientific Inc. Business Overview
7.14.2 Thermo Fisher Scientific Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.14.3 Thermo Fisher Scientific Inc. Human Microbiome Sequencing Technology Product Introduction
7.14.4 Thermo Fisher Scientific Inc. Response to COVID-19 and Related Developments
7.15 Viome, Inc.
7.15.1 Viome, Inc. Business Overview
7.15.2 Viome, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.15.3 Viome, Inc. Human Microbiome Sequencing Technology Product Introduction
7.15.4 Viome, Inc. Response to COVID-19 and Related Developments
7.16 CosmosID
7.16.1 CosmosID Business Overview
7.16.2 CosmosID Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.16.3 CosmosID Human Microbiome Sequencing Technology Product Introduction
7.16.4 CosmosID Response to COVID-19 and Related Developments
7.17 Leucine Rich Bio Pvt. Ltd.
7.17.1 Leucine Rich Bio Pvt. Ltd. Business Overview
7.17.2 Leucine Rich Bio Pvt. Ltd. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.17.3 Leucine Rich Bio Pvt. Ltd. Human Microbiome Sequencing Technology Product Introduction
7.17.4 Leucine Rich Bio Pvt. Ltd. Response to COVID-19 and Related Developments
7.18 Microba
7.18.1 Microba Business Overview
7.18.2 Microba Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.18.3 Microba Human Microbiome Sequencing Technology Product Introduction
7.18.4 Microba Response to COVID-19 and Related Developments
7.19 Microbiome Insights Inc.
7.19.1 Microbiome Insights Inc. Business Overview
7.19.2 Microbiome Insights Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.19.3 Microbiome Insights Inc. Human Microbiome Sequencing Technology Product Introduction
7.19.4 Microbiome Insights Inc. Response to COVID-19 and Related Developments
7.20 Molzym GmbH & Co. KG
7.20.1 Molzym GmbH & Co. KG Business Overview
7.20.2 Molzym GmbH & Co. KG Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.20.3 Molzym GmbH & Co. KG Human Microbiome Sequencing Technology Product Introduction
7.20.4 Molzym GmbH & Co. KG Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
9.1 About US
9.2 Disclaimer
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Human Microbiome Sequencing Technology Industry
1.7 COVID-19 Impact: Human Microbiome Sequencing Technology Market Trends
2 Global Human Microbiome Sequencing Technology Quarterly Market Size Analysis
2.1 Human Microbiome Sequencing Technology Business Impact Assessment - COVID-19
2.1.1 Global Human Microbiome Sequencing Technology Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Human Microbiome Sequencing Technology Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 By Players, Global Human Microbiome Sequencing Technology Quarterly Market Size, 2019 VS 2020
3.2 By Players, Human Microbiome Sequencing Technology Headquarters and Area Served
3.3 Date of Key Players Enter into Human Microbiome Sequencing Technology Market
3.4 Key Players Human Microbiome Sequencing Technology Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Human Microbiome Sequencing Technology Segments, By Type
4.1 Introduction
1.4.1 Traditional Sequencing Technologies
1.4.2 Next-Generation Sequencing
1.4.3 Third Generation Sequencing
4.2 By Type, Global Human Microbiome Sequencing Technology Market Size, 2019-2021
5 Impact of Covid-19 on Human Microbiome Sequencing Technology Segments, By Application
5.1 Overview
5.5.1 Research and Academic Institutions
5.5.2 Pharmaceutical and Biotechnology Companies
5.5.3 Hospital and Clinic
5.5.4 Others
5.2 By Application, Global Human Microbiome Sequencing Technology Market Size, 2019-2021
5.2.1 By Application, Global Human Microbiome Sequencing Technology Market Size by Application, 2019-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Baseclear B.V.
7.1.1 Baseclear B.V. Business Overview
7.1.2 Baseclear B.V. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.1.3 Baseclear B.V. Human Microbiome Sequencing Technology Product Introduction
7.1.4 Baseclear B.V. Response to COVID-19 and Related Developments
7.2 Beijing Genomics Institute (BGI) Genomics Co., Ltd
7.2.1 Beijing Genomics Institute (BGI) Genomics Co., Ltd Business Overview
7.2.2 Beijing Genomics Institute (BGI) Genomics Co., Ltd Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.2.3 Beijing Genomics Institute (BGI) Genomics Co., Ltd Human Microbiome Sequencing Technology Product Introduction
7.2.4 Beijing Genomics Institute (BGI) Genomics Co., Ltd Response to COVID-19 and Related Developments
7.3 Charles River Laboratories International Inc.
7.3.1 Charles River Laboratories International Inc. Business Overview
7.3.2 Charles River Laboratories International Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.3.3 Charles River Laboratories International Inc. Human Microbiome Sequencing Technology Product Introduction
7.3.4 Charles River Laboratories International Inc. Response to COVID-19 and Related Developments
7.4 Clinical Microbiomics A/S
7.4.1 Clinical Microbiomics A/S Business Overview
7.4.2 Clinical Microbiomics A/S Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.4.3 Clinical Microbiomics A/S Human Microbiome Sequencing Technology Product Introduction
7.4.4 Clinical Microbiomics A/S Response to COVID-19 and Related Developments
7.5 Eurofins Scientific SE
7.5.1 Eurofins Scientific SE Business Overview
7.5.2 Eurofins Scientific SE Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.5.3 Eurofins Scientific SE Human Microbiome Sequencing Technology Product Introduction
7.5.4 Eurofins Scientific SE Response to COVID-19 and Related Developments
7.6 GENEWIZ, Inc.
7.6.1 GENEWIZ, Inc. Business Overview
7.6.2 GENEWIZ, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.6.3 GENEWIZ, Inc. Human Microbiome Sequencing Technology Product Introduction
7.6.4 GENEWIZ, Inc. Response to COVID-19 and Related Developments
7.7 Illumina, Inc.
7.7.1 Illumina, Inc. Business Overview
7.7.2 Illumina, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.7.3 Illumina, Inc. Human Microbiome Sequencing Technology Product Introduction
7.7.4 Illumina, Inc. Response to COVID-19 and Related Developments
7.8 Novogene Corporation
7.8.1 Novogene Corporation Business Overview
7.8.2 Novogene Corporation Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.8.3 Novogene Corporation Human Microbiome Sequencing Technology Product Introduction
7.8.4 Novogene Corporation Response to COVID-19 and Related Developments
7.9 OraSure Technologies, Inc.
7.9.1 OraSure Technologies, Inc. Business Overview
7.9.2 OraSure Technologies, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.9.3 OraSure Technologies, Inc. Human Microbiome Sequencing Technology Product Introduction
7.9.4 OraSure Technologies, Inc. Response to COVID-19 and Related Developments
7.10 Oxford Nanopore Technologies, Inc.
7.10.1 Oxford Nanopore Technologies, Inc. Business Overview
7.10.2 Oxford Nanopore Technologies, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.10.3 Oxford Nanopore Technologies, Inc. Human Microbiome Sequencing Technology Product Introduction
7.10.4 Oxford Nanopore Technologies, Inc. Response to COVID-19 and Related Developments
7.11 Pacific Biosciences of California, Inc.
7.11.1 Pacific Biosciences of California, Inc. Business Overview
7.11.2 Pacific Biosciences of California, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.11.3 Pacific Biosciences of California, Inc. Human Microbiome Sequencing Technology Product Introduction
7.11.4 Pacific Biosciences of California, Inc. Response to COVID-19 and Related Developments
7.12 QIAGEN N.V.
7.12.1 QIAGEN N.V. Business Overview
7.12.2 QIAGEN N.V. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.12.3 QIAGEN N.V. Human Microbiome Sequencing Technology Product Introduction
7.12.4 QIAGEN N.V. Response to COVID-19 and Related Developments
7.13 Second Genome, Inc.
7.13.1 Second Genome, Inc. Business Overview
7.13.2 Second Genome, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.13.3 Second Genome, Inc. Human Microbiome Sequencing Technology Product Introduction
7.13.4 Second Genome, Inc. Response to COVID-19 and Related Developments
7.14 Thermo Fisher Scientific Inc.
7.14.1 Thermo Fisher Scientific Inc. Business Overview
7.14.2 Thermo Fisher Scientific Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.14.3 Thermo Fisher Scientific Inc. Human Microbiome Sequencing Technology Product Introduction
7.14.4 Thermo Fisher Scientific Inc. Response to COVID-19 and Related Developments
7.15 Viome, Inc.
7.15.1 Viome, Inc. Business Overview
7.15.2 Viome, Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.15.3 Viome, Inc. Human Microbiome Sequencing Technology Product Introduction
7.15.4 Viome, Inc. Response to COVID-19 and Related Developments
7.16 CosmosID
7.16.1 CosmosID Business Overview
7.16.2 CosmosID Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.16.3 CosmosID Human Microbiome Sequencing Technology Product Introduction
7.16.4 CosmosID Response to COVID-19 and Related Developments
7.17 Leucine Rich Bio Pvt. Ltd.
7.17.1 Leucine Rich Bio Pvt. Ltd. Business Overview
7.17.2 Leucine Rich Bio Pvt. Ltd. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.17.3 Leucine Rich Bio Pvt. Ltd. Human Microbiome Sequencing Technology Product Introduction
7.17.4 Leucine Rich Bio Pvt. Ltd. Response to COVID-19 and Related Developments
7.18 Microba
7.18.1 Microba Business Overview
7.18.2 Microba Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.18.3 Microba Human Microbiome Sequencing Technology Product Introduction
7.18.4 Microba Response to COVID-19 and Related Developments
7.19 Microbiome Insights Inc.
7.19.1 Microbiome Insights Inc. Business Overview
7.19.2 Microbiome Insights Inc. Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.19.3 Microbiome Insights Inc. Human Microbiome Sequencing Technology Product Introduction
7.19.4 Microbiome Insights Inc. Response to COVID-19 and Related Developments
7.20 Molzym GmbH & Co. KG
7.20.1 Molzym GmbH & Co. KG Business Overview
7.20.2 Molzym GmbH & Co. KG Human Microbiome Sequencing Technology Quarterly Revenue, 2020
7.20.3 Molzym GmbH & Co. KG Human Microbiome Sequencing Technology Product Introduction
7.20.4 Molzym GmbH & Co. KG Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
9.1 About US
9.2 Disclaimer
